|
1
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Freedman ND, Leitzmann MF, Hollenbeck AR,
Schatzkin A and Abnet CC: Cigarette smoking and subsequent risk of
lung cancer in men and women: Analysis of a prospective cohort
study. Lancet Oncol. 9:649–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hecht SS: Tobacco smoke carcinogens and
lung cancer. J Natl Cancer Inst. 91:1194–1210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peto R, Darby S, Deo H, Silcocks P,
Whitley E and Doll R: Smoking, smoking cessation, and lung cancer
in the UK since 1950 Combination of national statistics with two
case control studies. BMJ. 321:323–329. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matanić D, Beg-Zec Z, Stojanović D,
Matakorić N, Flego V and Milevoj-Ribić F: Cytokines in patients
with lung cancer. Scand J Immunol. 57:173–178. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koki AT and Masferrer JL: Celecoxib: A
specific COX-2 inhibitor with anticancer properties. Cancer
Control. 9 2 Suppl:S28–S35. 2002.
|
|
8
|
Hida T, Yatabe Y, Achiwa H, Muramatsu H,
Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi
T: Increased expression of cyclooxygenase 2 occurs frequently in
human lung cancers, specifically in adenocarcinomas. Cancer Res.
58:3761–3764. 1998.PubMed/NCBI
|
|
9
|
Fu JY, Masferrer JL, Seibert K, Raz A and
Needleman P: The induction and suppression of prostaglandin H2
synthase (cyclooxygenase) in human monocytes. J Biol Chem.
265:16737–16740. 1990.PubMed/NCBI
|
|
10
|
Tazawa R, Xu XM, Wu KK and Wang LH:
Characterization of the genomic structure, chromosomal location and
promoter of human prostaglandin H synthase-2 gene. Biochem Biophys
Res Commun. 203:190–199. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanabe T and Tohnai N: Cyclooxygenase
isozymes and their gene structures and expression. Prostaglandins
Other Lipid Mediat. 68(69): 95–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsujii M, Kawano S and DuBois RN:
Cyclooxygenase-2 expression in human colon cancer cells increases
metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta S, Srivastava M, Ahmad N, Bostwick
DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human
prostate adenocarcinoma. The Prostate. 42:73–78. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nam E, Lee SN, Im SA, Kim DY, Lee KE and
Sung SH: Expression of cyclooxygenase-2 in human breast cancer:
Relationship with HER-2/neu and other clinicopathological
prognostic factors. Cancer Res Treat. 37:165–170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zimmermann KC, Sarbia M, Weber AA,
Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in
human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
|
|
17
|
Wolff H, Saukkonen K, Anttila S,
Karjalainen A, Vainio H and Ristimäki A: Expression of
cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:4997–5001.
1998.PubMed/NCBI
|
|
18
|
Juuti A, Louhimo J, Nordling S, Ristimäki
A and Haglund C: Cyclooxygenase-2 expression correlates with poor
prognosis in pancreatic cancer. J Clin Pathol. 59:382–386. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang D and Dubois RN: Eicosanoids and
cancer. Nature Rev Cancer. 10:181–193. 2010. View Article : Google Scholar
|
|
20
|
Zha S, Yegnasubramanian V, Nelson WG,
Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: Progress and
perspective. Cancer Lett. 215:1–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papafili A, Hill MR, Brull DJ, McAnulty
RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter
variant in cyclooxygenase-2 represses gene expression: Evidence of
role in acute-phase inflammatory response. Arterioscler Thromb Vasc
Biol. 22:1631–1636. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Miao X, Tan W, Ning B, Liu Z,
Hong Y, Song W, Guo Y, Zhang X, Shen Y, et al: Identification of
functional genetic variants in cyclooxygenase-2 and their
association with risk of esophageal cancer. Gastroenterology.
129:565–576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T,
Zhang B, Zhao D, Yang M, Yu D and Lin D: Associations of functional
polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with
risk of occurrence and advanced disease status of colorectal
cancer. Carcinogenesis. 28:1197–1201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kristinsson JO, van Westerveld P, te
Morsche RH, Roelofs HM, Wobbes T, Witteman BJ, Tan AC, van Oijen
MG, Jansen JB and Peters WH: Cyclooxygenase-2 polymorphisms and the
risk of esophageal adeno- or squamous cell carcinoma. World J
Gastroenterol. 15:3493–3497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li D, Hao SH, Sun Y, Hu CM, Ma ZH, Wang
ZM, Liu J, Liu HB, Ye M, Zhang YF, et al: Functional Polymorphisms
in COX-2 gene are correlated with the risk of oral cancer. Biomed
Res Int. 2015:5806522015.PubMed/NCBI
|
|
26
|
Gou Q, Liu CH, Ben-Av P and Hla T:
Dissociation of basal turnover and cytokine-induced transcript
stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of
the 3′-untranslated region. Biochem Biophys Res Commun.
242:508–512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanak M, Szczeklik W and Szczeklik A:
Association of COX-2 gene haplotypes with prostaglandins production
in bronchial asthma. J Allergy Clin Immunol. 116:221–223. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Panguluri RC, Long LO, Chen W, Wang S,
Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W
and Kittles RA: COX-2 gene promoter haplotypes and prostate cancer
risk. Carcinogenesis. 25:961–966. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cox DG, Pontes C, Guino E, Navarro M,
Osorio A, Canzian F and Moreno V; Bellvitge Colorectal Cancer Study
Group, : Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2
(PTGS2/COX2) and risk of colorectal cancer. Br J Cancer.
91:339–343. 2004.PubMed/NCBI
|
|
30
|
Piranda DN, Festa-Vasconcellos JS, Amaral
LM, Bergmann A and Vianna-Jorge R: Polymorphisms in regulatory
regions of cyclooxygenase-2 gene and breast cancer risk in
Brazilians: A case-control study. BMC Cancer. 10:6132010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soslow RA, Dannenberg AJ, Rush D, Woerner
BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human
pulmonary, colonic, and mammary tumors. Cancer. 89:2637–2645. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo Y, Zhang X, Tan W, Miao X, Sun T, Zhao
D and Lin D: Platelet 12-lipoxygenase Arg261Gln polymorphism:
Functional characterization and association with risk of esophageal
squamous cell carcinoma in combination with COX-2 polymorphisms.
Pharmacogenet Genomics. 17:197–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lurje G, Nagashima F, Zhang W, Yang D,
Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD,
et al: Polymorphisms in cyclooxygenase-2 and epidermal growth
factor receptor are associated with progression-free survival
independent of K-ras in metastatic colorectal cancer patients
treated with single-agent cetuximab. Clin Cancer Res. 14:7884–7895.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coskunpinar E, Eraltan IY, Turna A and
Agachan B: Cyclooxygenase-2 gene and lung carcinoma risk. Med
Oncol. 28:1436–1440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ueda N, Maehara Y, Tajima O, Tabata S,
Wakabayashi K and Kono S: Genetic polymorphisms of cyclooxygenase-2
and colorectal adenoma risk: The Self Defense Forces Health Study.
Cancer Sci. 99:576–581. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao J, Kang HF, Ma XB, Tang W, Liu D, Zhao
Y, Zhang SQ, Guan HT, Lin S, Ren HT, et al: Functional promoter
−765 G > C variant in COX-2 gene is associated with the
susceptibility of breast cancer in Chinese Han women. Cancer cell
Int. 14:382014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang XF, Huang MZ, Zhang XW, Hua RX and
Guo WJ: COX-2-765G>C polymorphism increases the risk of cancer:
A meta-analysis. PLoS One. 8:e732132013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang Z, Nie ZL, Pan Y, Zhang L, Gao L,
Zhang Q, Qu L, He B, Song G, Zhang Y and Shukui Wang: The Cox-2
−1195 G >A polymorphism and cancer risk: A meta-analysis of 25
case-control studies. Mutagenesis. 26:729–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan F, Tian J, Pan Y and Zhang Y: Lack of
association of the cyclooxygenase 8473 T>C polymorphism with
lung cancer: Evidence from 9841 subjects. Asian Pac J Cancer Prev.
12:1941–1945. 2011.PubMed/NCBI
|
|
41
|
Vogel U, Christensen J, Wallin H, Friis S,
Nexø BA, Raaschou-Nielsen O, Overvad K and Tjønneland A:
Polymorphisms in genes involved in the inflammatory response and
interaction with NSAID use or smoking in relation to lung cancer
risk in a prospective study. Mutat Res. 639:89–100. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wistuba II, Berry J, Behrens C, Maitra A,
Shivapurkar N, Milchgrub S, Mackay B, Minna JD and Gazdar AF:
Molecular changes in the bronchial epithelium of patients with
small cell lung cancer. Clin Cancer Res. 6:2604–2610.
2000.PubMed/NCBI
|
|
46
|
Bhat IA, Rasool R, Qasim I, Masoodi KZ,
Paul SA, Bhat BA, Ganaie FA, Aziz SA and Shah ZA: COX-2
overexpression and 8473 T/C polymorphism in 3′ UTR in non-small
cell lung cancer. Tumour Biol. 35:11209–11218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G,
Lin D and Wang L: Cyclooxygenase-2 genetic variants are associated
with survival in unresectable locally advanced non-small cell lung
cancer. Clin Cancer Res. 16:2383–2390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Koki AT, Khan NK, Woerner BM, Seibert K,
Harmon JL, Dannenberg AJ, Soslow RA and Masferrer JL:
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis
in human epithelial cancers: Evidence for potential clinical
utility of COX-2 inhibitors in epithelial cancers. Prostaglandins
Leukot Essent Fatty Acids. 66:13–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Krzystyniak KL: Current strategies for
anticancer chemoprevention and chemoprotection. Acta Pol Pharm.
59:473–478. 2002.PubMed/NCBI
|
|
50
|
Guo X, Chen Y, Xu Z, Xu Z, Qian Y and Yu
X: Prognostic significance of VEGF-C expression in correlation with
COX-2, lymphatic microvessel density, and clinicopathologic
characteristics in human non-small cell lung cancer. Acta Biochim
Biophys Sin (Shanghai). 41:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhan P, Qian Q and Yu LK: Prognostic value
of COX-2 expression in patients with non-small cell lung cancer: A
systematic review and meta-analysis. J Thorac Dis. 5:40–47.
2013.PubMed/NCBI
|
